Very glad to contribute to this large (11 trials, 2500 pts) meta-analysis led by @G_Villacampa, now out in @TheLancetOncol. Half of the pts had high HER2DX risk score and were found to have a significantly higher risk of recurrence, irrespective of pCR/RD. https://t.co/cXnwkARMzd
Hoy acabamos con gran satisfacción 😊 los 1os talleres de #pocus en #SEOM24, impartidos por internistas y oncólogas del 🏨#HUIC.>30 oncólog@s de todas partes descubriendo lo fácil y útil que es la eco clínica. Gracias @_SEOM por hacerlo posible, y ojalá 🤞 vengan muchos +!
Otras dos grandes profesionales que nos honrarán con su participación en el #BestofBreast2023 del próximo martes, la Dra. Coralia Bueno (HU Infanta Cristina) a cargo de la presentación y la Dra. Ruth Espinosa (HG La Mancha Centro) como moderadora ❤️
#16ENEMamaCentro#BreastCancer
Keynote 522, beginning to see curves diverge in pCR groups possibly indicating longterm immunity benefits with pembrolizumab in pCR arm. Still does not answer question of adjuvant pembrolizumab being answered in OPTIMICE pCR.
#bcsm
Is BMI a predictive factor for efficacy of taxane-based chemotherapy in early BC patients?
Our #ESMO23 poster 251P is ready! Feel free to come and share your thoughts and questions with @JAGarciaSaenz, PI of this study. Thanks you to all the parts!
@myESMO@OncoAlert
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic #breastcancer patients #ESMO21@myESMO
https://t.co/R7qcaoaonn
* OS data immature ⏱️, trend to benefit w/ T-DXd
* ✅ORR 34 vs. 80% in favor of T-DXd
* 🫁 ILD 2% T-DM1 vs. 10% T-DXd, but NO 👏👏G4/5 cases (only 0.8% G3) now (we have figured out how to catch this early now)
* 🔄pretty similar rates of AEs
#bcsm@OncoAlert#ESMO21
🔔 🔔 COMUNICADO GECP-VACUNACIÓN COVID PACIENTES #CANCERDEPULMON
👉 No hay datos que avalen + riesgo de efectos secundarios
👉 Debería vacunarse en cuanto esté disponible.
👉 Deben mantenerse medidas de protección y priorizar vacunación a familiares y cuidadores.